91637-76-2 Usage
Uses
Used in Pharmaceutical Industry:
4-[3-(dimethylamino)propoxy]benzylamine is used as a precursor in the synthesis of various pharmaceuticals due to its ability to be chemically modified to create a wide array of medicinal compounds.
Used in Agrochemical Industry:
In the agrochemical sector, 4-[3-(dimethylamino)propoxy]benzylamine is utilized as a starting material for the production of different agrochemicals, contributing to the development of pesticides and other agricultural chemicals.
Used in Dye and Pigment Production:
4-[3-(dimethylamino)propoxy]benzylamine is employed in the manufacturing process of dyes and pigments, leveraging its chemical properties to produce a spectrum of colorants for various applications.
4-[3-(dimethylamino)propoxy]benzylamine's diverse applications stem from its adaptable chemical structure, which allows for its integration and modification in multiple chemical processes and products.
Check Digit Verification of cas no
The CAS Registry Mumber 91637-76-2 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 9,1,6,3 and 7 respectively; the second part has 2 digits, 7 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 91637-76:
(7*9)+(6*1)+(5*6)+(4*3)+(3*7)+(2*7)+(1*6)=152
152 % 10 = 2
So 91637-76-2 is a valid CAS Registry Number.
91637-76-2Relevant academic research and scientific papers
Solid dispersions containing an apoptosis-inducing agent
-
Page/Page column 137, (2019/03/15)
A pro-apoptotic solid dispersion comprises, in essentially non-crystalline form, a Bcl-2 family protein inhibitory compound of Formula I as defined herein, dispersed in a solid matrix that comprises (a) a pharmaceutically acceptable water-soluble polymeric carrier and (b) a pharmaceutically acceptable surfactant. A process for preparing such a solid dispersion comprises dissolving the compound, the polymeric carrier and the surfactant in a suitable solvent, and removing the solvent to provide a solid matrix comprising the polymeric carrier and the surfactant and having the compound dispersed in essentially non-crystalline form therein. The solid dispersion is suitable for oral administration to a subject in need thereof for treatment of a disease characterized by overexpression of one or more anti-apoptotic Bcl-2 family proteins, for example cancer.
